Prestige Consumer Healthcare Inc. Announces New $25 Million Share Repurchase Program, Participation in the Raymond James Institutional Investors Conference

TARRYTOWN, N.Y., March 02, 2020 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that the Company’s Board of Directors authorized the repurchase of up to $25.0 million of the Company’s issued and outstanding common stock.  Separately, the Company plans to present at the Raymond James Institutional Investors Conference at 8:40 a.m. ET today, March 2nd.

Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare, said, "Today’s share repurchase program announcement demonstrates the Board and management’s continued confidence in the long-term growth prospects of Prestige and our proven three pillar strategy focused around organic growth, free cash flow and capital allocation to drive shareholder value.  The authorized repurchases are part of the ongoing commitment to a disciplined and opportunistic capital deployment strategy that is enabled by our robust financial profile.  We look forward to discussing our business strategy in greater detail at the Raymond James conference later today.”

Share Repurchase Details

Under the approved authorization, the Company may purchase common stock through March, 2021 utilizing one or more open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions or otherwise, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the Securities and Exchange Commission.

The timing of the purchases and the amount of stock repurchased is subject to the Company's discretion and will depend on market and business conditions, applicable legal and credit requirements and other corporate considerations including the Company’s historical strategy of pursuing accretive acquisitions and deleveraging.

41st Annual Raymond James Conference

The Company is presenting at the Raymond James 41^st Annual Institutional Investors Conference today, March 2^nd at 8:40 a.m. ET.  The presentation will be webcast live and can be accessed on the Company’s website, www.prestigeconsumerhealthcare.com, and will remain available as an archived replay for one week following the presentation date.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, Gaviscon antacid in Canada, and Hydralyte rehydration products and the Fess line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.